Research ArticleDrug Discovery and Translational Medicine
Open Access
Danirixin: A Reversible and Selective Antagonist of the CXC Chemokine Receptor 2
Jakob Busch-Petersen, Donald C. Carpenter, Miriam Burman, James Foley, Gerald E. Hunsberger, David J. Kilian, Michael Salmon, Ruth J. Mayer, John G. Yonchuk and Ruth Tal-Singer
Journal of Pharmacology and Experimental Therapeutics August 2017, 362 (2) 338-346; DOI: https://doi.org/10.1124/jpet.117.240705
Jakob Busch-Petersen
GSK R&D, King of Prussia PA
Donald C. Carpenter
GSK R&D, King of Prussia PA
Miriam Burman
GSK R&D, King of Prussia PA
James Foley
GSK R&D, King of Prussia PA
Gerald E. Hunsberger
GSK R&D, King of Prussia PA
David J. Kilian
GSK R&D, King of Prussia PA
Michael Salmon
GSK R&D, King of Prussia PA
Ruth J. Mayer
GSK R&D, King of Prussia PA
John G. Yonchuk
GSK R&D, King of Prussia PA
Ruth Tal-Singer
GSK R&D, King of Prussia PA

Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleDrug Discovery and Translational Medicine
Danirixin: A Reversible and Selective Antagonist of CXCR2
Jakob Busch-Petersen, Donald C. Carpenter, Miriam Burman, James Foley, Gerald E. Hunsberger, David J. Kilian, Michael Salmon, Ruth J. Mayer, John G. Yonchuk and Ruth Tal-Singer
Journal of Pharmacology and Experimental Therapeutics August 1, 2017, 362 (2) 338-346; DOI: https://doi.org/10.1124/jpet.117.240705
Research ArticleDrug Discovery and Translational Medicine
Danirixin: A Reversible and Selective Antagonist of CXCR2
Jakob Busch-Petersen, Donald C. Carpenter, Miriam Burman, James Foley, Gerald E. Hunsberger, David J. Kilian, Michael Salmon, Ruth J. Mayer, John G. Yonchuk and Ruth Tal-Singer
Journal of Pharmacology and Experimental Therapeutics August 1, 2017, 362 (2) 338-346; DOI: https://doi.org/10.1124/jpet.117.240705
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement